6 Aug 15
Zynerba Pharmaceuticals Builds Out Board of Directors

High-caliber appointees offer track record of success in building innovative pharmaceutical companies as company closes IPO

Devon, PA, August 6, 2015 – Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), announced today that it has appointed six new members of its board of directors. The appointees offer extensive scientific, regulatory commercial and financial experience and successful track records in development- and commercial-stage pharmaceutical companies. With these new appointments, Philip Wagenheim and Steve Gailar have resigned as members of the Zynerba board of directors.

The new Zynerba board appointments are as follows. Full biographies are available at zynerba.com.

Warren D. Cooper, MB, BS, BSc, MPFM
Former CEO, Prism Pharmaceuticals; Merck, Sharp, Dohme

William J. Federici, MBA, CPA
Vice President and Chief Financial Officer of West Pharmaceutical Services

Thomas L. Harrison, LH.D
Chairman Emeritus of Diversified Agency Services, a division of Omnicom Group

Daniel L. Kisner, MD
Former venture partner/partner, Aberdare Ventures; President and CEO, Caliper Technologies

Kenneth I. Moch
President, Euclidean Life Science Advisors; Former President and CEO, Chimerix, BioMedical Enterprises, Alteon, and Biocyte Corporation

Cynthia Rask, MD
Board certified in Clinical Neurophysiology; Former Acting Director, Office of Cellular, Tissue and Gene Therapies US Food and Drug Administration (FDA); Abbott Laboratories, Genentech

“These high-caliber board appointments well-position Zynerba, the first and only transdermal cannabinoid company, for its continued development,” said Armando Anido, Chief Executive Officer (CEO) and Chairman of Zynerba Pharmaceuticals. “With such a broad range of expertise, we are confident that the board will strategically guide the company as we rapidly approach clinical development in the coming months and ultimately pursue regulatory approval and commercialization of our novel transdermal cannabinoid treatments for patients in need. We thank Phil and Steve for their support and guidance and for successfully positioning Zynerba for its introduction to the public market.”

About Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals (NASDAQ: ZYNE) is a specialty pharmaceutical company focused on developing and commercializing proprietary next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery. Zynerba is evaluating two product candidates, ZYN002 and ZYN001, in five indications. ZYN002, the company’s CBD Gel, is the first and only synthetic CBD formulated as a patent protected permeation-enhanced gel and is being studied in refractory epilepsy, Fragile X syndrome and osteoarthritis. Zynerba is also developing ZYN001, which utilizes a synthetically manufactured pro-drug of THC in a transdermal patch to deliver THC through the skin and into the bloodstream. ZYN001 will be studied in fibromyalgia and peripheral neuropathic pain. Learn more at www.zynerba.com and follow the company on Twitter at @ZynerbaPharma.

Investor Contacts
Armando Anido, Chairman and CEO
Richard Baron, CFO
Zynerba Pharmaceuticals
484.581.7505

Media Contact
Jennifer Guinan
Sage Strategic Marketing
610.410.8111
Jennifer@sagestrat.com

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the company’s current expectations. For example, there can be no guarantee that we will obtain approval for ZYN002 or ZYN001 from the U.S. Food and Drug Administration (“FDA”) or foreign regulatory authorities; even if ZYN002 or ZYN001 are approved, we may not be able to obtain the label claims that we are seeking from the FDA. Management’s expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: our ability to commercialize our product candidates; the size and growth potential of the markets for our product candidates, and our ability to service those markets; our ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of our product candidates; the success, cost and timing of our product development activities, studies and clinical trials; the success of competing products that are or become available; and our expectations regarding our ability to obtain and adequately maintain sufficient intellectual property protection for our product candidates. These and other risks are described under the heading “Risk Factors” the registration statement on Form S-1 (commission file number 333-205355), which was declared effective by the Securities and Exchange Commission on August 4, 2015. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.